[1] Her work on Canavan disease started at Yale, where she collaborated with other early pioneers in gene therapy.
She left Yale in 1998 to join the (now defunct) Cell & Gene Therapy Center at Thomas Jefferson University in Philadelphia.
She directs The Cell & Gene Therapy Center at the University of Medicine and Dentistry of New Jersey.
She is generating pre-clinical data using human Embryonic-Derived-Oligodendrocyte Stem Cells provided by Geron Corporation (CA).
These studies will provide a foundation for a targeted and comprehensive analysis of the potential of a cell-based therapy for Canavan Disease.